div class=ts-pagebutton class=gotoPage data-page=1Page 1button div class=ts-imageimg data-url=a-new-ink-on-pharma-life-a-quarterly-news-letter-from-dept-diabetes-januaryhtmlpage=1 data-page=1 class=ts-thumb lazyload alt=Page 1: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader030vdocumentsnetreader030viewer20220406055ea963c5a092d923cc000147html5thumbnails1jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=2Page 2button div class=ts-imageimg data-url=a-new-ink-on-pharma-life-a-quarterly-news-letter-from-dept-diabetes-januaryhtmlpage=2 data-page=2 class=ts-thumb lazyload alt=Page 2: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader030vdocumentsnetreader030viewer20220406055ea963c5a092d923cc000147html5thumbnails2jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=3Page 3button div class=ts-imageimg data-url=a-new-ink-on-pharma-life-a-quarterly-news-letter-from-dept-diabetes-januaryhtmlpage=3 data-page=3 class=ts-thumb lazyload alt=Page 3: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader030vdocumentsnetreader030viewer20220406055ea963c5a092d923cc000147html5thumbnails3jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=4Page 4button div class=ts-imageimg data-url=a-new-ink-on-pharma-life-a-quarterly-news-letter-from-dept-diabetes-januaryhtmlpage=4 data-page=4 class=ts-thumb lazyload alt=Page 4: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader030vdocumentsnetreader030viewer20220406055ea963c5a092d923cc000147html5thumbnails4jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=5Page 5button div class=ts-imageimg data-url=a-new-ink-on-pharma-life-a-quarterly-news-letter-from-dept-diabetes-januaryhtmlpage=5 data-page=5 class=ts-thumb lazyload alt=Page 5: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader030vdocumentsnetreader030viewer20220406055ea963c5a092d923cc000147html5thumbnails5jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=6Page 6button div class=ts-imageimg data-url=a-new-ink-on-pharma-life-a-quarterly-news-letter-from-dept-diabetes-januaryhtmlpage=6 data-page=6 class=ts-thumb lazyload alt=Page 6: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader030vdocumentsnetreader030viewer20220406055ea963c5a092d923cc000147html5thumbnails6jpg width=140 height=200 divdiv
